Aspirin, superoxide anions and development of hypertension.
Bobik
Alex
A
D000804:Angiotensin II / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use; D001011:Aorta / Q000166:cytology; D001241:Aspirin / Q000494:pharmacology* / Q000627:therapeutic use; D002478:Cells, Cultured; D006973:Hypertension / Q000209:etiology* / Q000517:prevention & control; D019808:Losartan / Q000494:pharmacology; D008163:Luminescent Measurements; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013481:Superoxides / Q000378:metabolism*; D013997:Time Factors; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D000959:Antihypertensive Agents; D000975:Antioxidants; D014662:Vasoconstrictor Agents; D013481:Superoxides; D000804:Angiotensin II; D019808:Losartan; D001241:Aspirin